Lipoteichoic acid

Synonyms: 脂磷壁酸
Lipoteichoic acid 是一种口服有效的抗炎剂和抗肿瘤剂,作为革兰氏阳性菌中重要的免疫分子,它可通过诱导 C3 和抑制 CD55 激活补体系统,通过 PI3K/Akt/mTOR 通路调控巨噬细胞自噬 (autophagy),在小鼠中诱导肺损伤,并抑制黑色素的产生。
产品编号: MS-A71847 CAS No.: 56411-57-5
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Lipoteichoic acid 是一种口服有效的抗炎剂和抗肿瘤剂,作为革兰氏阳性菌中重要的免疫分子,它可通过诱导 C3 和抑制 CD55 激活补体系统,通过 PI3K/Akt/mTOR 通路调控巨噬细胞自噬 (autophagy),在小鼠中诱导肺损伤,并抑制黑色素的产生。

生物实验数据

生物活性 Lipoteichoic acid is an orally active anti-inflammatory and antitumor agent that, as an important immune molecule in Gram-positive bacteria, activates the complement system by inducing C3 and inhibiting CD55, regulates macrophage autophagy through the PI3K/Akt/mTOR pathway, induces lung injury in mice, and inhibits melanin production.
体外研究
(In Vitro)

Lipoteichoic acid (0.1-20 μg/mL;12-48 小时) 通过抑制 PI3K/AKT/mTOR 通路诱导巨噬细胞自噬。
Lipoteichoic acid (0.1-100 μg/mL;24 小时) 在 B16F10 细胞中通过 MITF、 ERK 和 PI3K/AKT 信号通路抑制黑色素的产生。
Lipoteichoic acid (50-100 ng/mL;2-3 小时) 对 HT-29 细胞无细胞毒性,在 LPS (MS-X54539) 处理的 HT-29 细胞中降低 TNF-α 的分泌和提高 IL-10 的分泌。

Western Blot Analysis

Cell Line: macrophage
Concentration: 0.1, 1, 10, and 20 μg/mL
Incubation Time: 12, 24 and 48 h
Result: Significantly decreased the expression levels of p-Akt and p-mTOR protein, but did not affect the expression of Akt and mTOR protein.

Western Blot Analysis

Cell Line: B16F10 cells
Concentration: 0.1, 1, 10 and 100 μg/mL
Incubation Time: 24 h
Result: Reduced the level of MITF in a dose-dependent manner.
Increased the phosphorylation levels of ERK, AKT and PI3K.
体内研究
(In Vivo)

Lipoteichoic acid (800 μg/100 μL;灌胃;7 天) 在结肠炎小鼠模型中具有改善作用。
Lipoteichoic acid (0.1 mg;口服;20 天-34 周) 在 UV 诱导的肿瘤模型中具有免疫调节和保护作用。
Lipoteichoic acid (5 mg/kg;气管内注射;单剂量) 在小鼠中可诱导肺损伤。

Animal Model: DSS (MS-A45736) treated male swiss albino mice aged 6-8 weeks old
Dosage: 800 μg/100 μL
Administration: Oral gavage (i.g.); 7 days
Result: Significantly improved external colitis symptoms, disease activity scores, and weight gain in colitis mice.
Significantly improved key inflammatory markers such as the gut permeability, myeloperoxidase activity and histopathological damages in colon in colitis mice.
Animal Model: Female Crl:SKH-1-hrBR hairless mice aged 8-12 weeks old (20-25 g) with UV-induced tumors
Dosage: 100 μL (1 mg/mL)
Administration: Oral administration; 20 days and 34 weeks (3 times a week)
Result: Caused T cells in the mouse inguinal lymph nodes to produce higher levels of interferon-γ and a number of total, helper and cytotoxic T cells.
Significantly delayed the appearance of tumors.
Animal Model: Male C57BL/6 mice aged 6‑8 weeks old (22±3 g)
Dosage: 5 mg/kg
Administration: Intratracheal injection; Single dose
Result: Induced inflammatory cell infiltration, inter‑alveolar septal thickening and alveolar collapse.
Promoted the concentration of BALF total protein and the expression of inflammatory factors.
Increased lung neutrophil infiltration and MPO activity.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT04071561University of Basel|Kantonsspital Aarau
Adrenal Tumor|Adrenal Mass|Pheochromocytoma|Conn Adenoma|Adrenal Metastases|Adrenal Hyperplasia
2018-11-19
NCT04111874Baylor College of Medicine
Cognitive Behavioral Therapy|Autism Spectrum Disorder|Anxiety Disorders|Obsessive-Compulsive Disorder|Social Anxiety Disorder|Generalized Anxiety Disorder|Specific Phobia
2019-07-30NA
性状 固体
颜色 White to off-white

化学信息

CAS No. 56411-57-5
别名 脂磷壁酸

储存&溶解度

溶解度信息
DMSO: 80 mg/mL, Sonication is recommended.
H2O: 5 mg/mL, Sonication is recommended.
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础